Immunotherapy and Targeting the Tumor Microenvironment: Current Place and New Insights in Primary Pulmonary NUT Carcinoma.
Immunotherapy and Targeting the Tumor Microenvironment: Current Place and New Insights in Primary Pulmonary NUT Carcinoma.
复制标题
DOI：
10.3389/fonc.2021.690115
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Dong Y
中科院分区：
文献类型：
--
作者：
Li X;Shi H;Zhang W;Bai C;He M;Ta N;Huang H;Ning Y;Fang C;Qin H;Dong Y
原发性肺睾丸癌是一种罕见的高度侵袭性的恶性肿瘤。它约占胸部原发性肿瘤的0.22%，但人们对它的认识很少，因此常被误诊为肺鳞状细胞癌。目前尚未形成有效的治疗方法，预后极差。本文就睾丸癌原发性肺核蛋白的病因、发病机制、诊断、治疗和预后等方面进行综述，以期更好地认识睾丸癌原发性肺核蛋白，并探讨目前的和创新的克服策略。随着肿瘤免疫治疗和肿瘤微环境的日益重要，本文还讨论了免疫治疗和靶向肿瘤微环境是否能改善睾丸癌原发性肺核蛋白的预后。以及可能的治疗策略。我们回顾和总结了所有接受免疫治疗的原发性睾丸癌肺核蛋白患者的临床病理特征，包括首次误诊、疾病分期、肿瘤新生血管相关的免疫组化标志物以及免疫治疗相关的生物标志物，如PD-L1（程序性死亡配体1）和TMB（肿瘤突变负荷）。同时，我们总结和分析了PD-1（程序性细胞死亡蛋白1）/PD-L1抑制剂治疗原发性睾丸癌肺核蛋白患者的无进展生存期（PFS）和总生存期（OS），并探索可能受益于免疫治疗的潜在人群。就我们所知，这是第一次对睾丸癌原发性肺核蛋白的肿瘤微环境和免疫治疗效果的探索进行综述。
Primary pulmonary nuclear protein of testis carcinoma is a rare and highly aggressive malignant tumor. It accounts for approximately 0.22% of primary thoracic tumors and is little known, so it is often misdiagnosed as pulmonary squamous cell carcinoma. No effective treatment has been formed yet, and the prognosis is extremely poor. This review aims to summarize the etiology, pathogenesis, diagnosis, treatment, and prognosis of primary pulmonary nuclear protein of testis carcinoma in order to better recognize it and discuss the current and innovative strategies to overcome it. With the increasing importance of cancer immunotherapy and tumor microenvironment, the review also discusses whether immunotherapy and targeting the tumor microenvironment can improve the prognosis of primary pulmonary nuclear protein of testis carcinoma and possible treatment strategies. We reviewed and summarized the clinicopathological features of all patients with primary pulmonary nuclear protein of testis carcinoma who received immunotherapy, including initial misdiagnosis, disease stage, immunohistochemical markers related to tumor neovascularization, and biomarkers related to immunotherapy, such as PD-L1 (programmed death-ligand 1) and TMB (tumor mutational burden). In the meanwhile, we summarized and analyzed the progression-free survival (PFS) and the overall survival (OS) of patients with primary pulmonary nuclear protein of testis carcinoma treated with PD-1 (programmed cell death protein 1)/PD-L1 inhibitors and explored potential population that may benefit from immunotherapy. To the best of our knowledge, this is the first review on the exploration of the tumor microenvironment and immunotherapy effectiveness in primary pulmonary nuclear protein of testis carcinoma.
登录
查看更多内容
影响因子：
6.2
作者：
Chau NG;Hurwitz S;Mitchell CM;Aserlind A;Grunfeld N;Kaplan L;Hsi P;Bauer DE;Lathan CS;Rodriguez-Galindo C;Tishler RB;Haddad RI;Sallan SE;Bradner JE;French CA
通讯作者：
French CA
影响因子：
10.5
作者：
Alekseyenko AA;Walsh EM;Wang X;Grayson AR;Hsi PT;Kharchenko PV;Kuroda MI;French CA
通讯作者：
French CA
影响因子：
8.4
作者：
Ameratunga, Malaka;Chenard-Poirier, Maxime;Lopez, Juanita
通讯作者：
Lopez, Juanita
影响因子：
2.5
作者：
Cao, Jiashun;Chen, Donghong;Zhao, Chuanduo
通讯作者：
Zhao, Chuanduo
影响因子：
3.6
作者：
Ding, Tingting;Wang, Yajin;Du, Yuqing
通讯作者：
Du, Yuqing